QUESTION ASKED: Can a clinical oncology massage program be safely and effectively integrated into chemoinfusion units to provide symptom control for patients with breast cancer receiving chemotherapy?SUMMARY ANSWER: A clinical oncology massage program can be safely and effectively implemented into chemoinfusion suites by addressing common patient-level barriers to access of cost, time, and travel, and the institutional-level barrier of space.
WHAT WE DID:We developed an integrative oncology massage program for patients with breast cancer in private chemoinfusion suites at an academic hospital and evaluated its outcomes using tablet-based technology.WHAT WE FOUND: The program was well received with no adverse events noted. Patients reported significant decreases in anxiety, nausea, pain, and fatigue.
BIAS, CONFOUNDING FACTORS, REAL-LIFE IMPLICATIONS:We evaluated the immediate effect of oncology massage on symptom control. This approach, along with the potential for bias due to social desirability and the lack of a control group, may overestimate the benefit of massage. Despite the limitations, our study provides initial evidence that an oncology massage program can be safely and effectively integrated into chemoinfusion suites to provide symptom relief to patients with breast cancer.
Materials and MethodsWe describe the development and implementation of an oncology massage program embedded into chemoinfusion suites. We used deidentified program evaluation data to identify specific reasons individuals refuse massage and to evaluate the immediate impact of massage treatments on patient-reported outcomes using a modified version of the Distress Thermometer delivered via iPad. We analyzed premassage and postmassage data from the Distress Thermometer using paired t test and derived qualitative data from participants who provided written feedback on their massage experiences.
ResultsOf the 1,090 massages offered, 692 (63%) were accepted. We observed a significant decrease in self-reported anxiety (from 3.9 to 1.7), nausea (from 2.5 to 1.2), pain (from 3.3 to 1.9), and fatigue (from 4.8 to 3.0) premassage and postmassage, respectively (all P , .001). We found that 642 survey participants (93%) were satisfied with their massage, and 649 (94%) would recommend it to another patient undergoing treatment. Spontaneous patient responses overwhelmingly endorsed the massage as relaxing. No adverse events were reported. Among the 398 patients (36%) who declined a massage, top reasons were time concerns and lack of interest.
ConclusionA clinical oncology massage program can be safely and effectively integrated into chemoinfusion units to provide symptom control for patients with breast cancer. This integrative approach overcomes patient-level barriers of cost, time, and travel, and addresses the institutional-level barrier of space.